January 31, 2017—The Department of Health and Human and Human Services has withdrawn the final 340B program mega-guidance from White House review. The Office of Budget and Management announced the action on its Reginfo.gov website. On Jan. 20, the Trump Administration asked all federal departments and agencies to freeze pending regulations and guidance documents – presumably … [Read more...]
Senator Slams CMS Response to Questions About EpiPen
January 26, 2017—Sen. Chuck Grassley (R-Iowa) is ramping up pressure on the Centers for Medicare and Medicaid Services to hand over documents about Mylan Pharmaceuticals’ misclassification of EpiPen as a generic drug and subsequent underpayment of Medicaid rebates. … [Read more...]
Trump Administration Freezes Regulations, Presumably Including 340B Mega-guidance
January 25, 2017—The Trump administration has asked federal departments and agencies to freeze pending regulations and guidance documents – presumably including the 340B mega-guidance – for review by an administration appointee or designee. Incoming administrations commonly embargo the preceding presidency’s newest and planned rules. … [Read more...]
Studies Lift Lid on Drug Industry Influence Peddling
January 18, 2017—Patient advocacy groups and private practice oncologists frequently parrot the drug industry about the 340B drug discount program. New research in JAMA Internal Medicine sheds light on why that might be. … [Read more...]
Trump: Big Pharma “Getting Away With Murder”
January 11, 2017—President-elect Trump said today that drug companies are “getting away with murder” as he promised to save the country billions of dollars through “new bidding procedures.” … [Read more...]
Pricey Cancer and Orphan Drugs Dominate Pipeline
January 9, 2017—Cancer and orphan drugs that command high prices increasingly dominate drug company pipelines, a new study shows. … [Read more...]
New 340B Rule Lets Feds Fine Drugmakers for Overcharges
January 4, 2017—The Department of Health and Human Services published a 340B program final rule today implementing fines for drug manufacturers that knowingly and intentionally overcharge safety-net healthcare providers. The rule also sets standards for calculating 340B ceiling prices. … [Read more...]